Table 5.

Association between total HCA and MeIQ estimate and colorectal adenoma risk according to NAT2 acetylation genotype

NAT2 acetylation genotype
MenWomen
Quartile (Q)Slow/intermediateRapidSlow/intermediateRapid
NOR (95% CI)aNOR (95% CI)aNOR (95% CI)aNOR (95% CI)a
HCA
 Q141/451.00 (ref.)56/581.07 (0.59–1.91)18/281.00 (ref.)20/270.93 (0.38–2.23)
 Q278/471.97 (1.10–3.54)56/541.11 (0.62–2.00)20/261.00 (0.41–2.44)24/241.18 (0.49–2.82)
 Q344/610.82 (0.45–1.50)62/381.77 (0.96–3.26)35/321.22 (0.54–2.77)31/241.43 (0.61–3.34)
 Q464/501.36 (0.75–2.44)46/570.83 (0.46–1.52)36/271.81 (0.77–4.23)33/281.53 (0.67–3.50)
Pinteraction0.810.84
MeIQ
 Q145/451.00 (ref.)56/550.98 (0.55–1.76)15/271.00 (ref.)18/260.94 (0.37–2.39)
 Q265/491.39 (0.78–2.50)64/571.11 (0.63–1.96)29/291.49 (0.62–3.55)22/221.35 (0.54–3.38)
 Q355/620.92 (0.52–1.63)49/371.28 (0.69–2.39)31/261.75 (0.72–4.23)28/291.47 (0.63–3.47)
 Q462/471.21 (0.67–2.17)51/580.79 (0.44–1.43)34/311.68 (0.71–3.93)40/262.26 (0.96–5.30)
Pinteraction0.600.54

Abbreviation: N, number of cases/controls.

  • aAdjusted for age, screening period, smoking, alcohol consumption, body mass index, physical activity, family history of colorectal cancer, and NSAID use. Further adjusted for age at menarche, menopausal status, and current use of hormones in women.